NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,991,826 | -4.6% | 253,413 | +21.2% | 0.00% | – |
| Q2 2023 | $2,088,880 | -7.0% | 209,097 | -17.3% | 0.00% | – |
| Q1 2023 | $2,245,860 | -48.9% | 252,912 | -36.8% | 0.00% | – |
| Q4 2022 | $4,396,634 | -29.8% | 400,422 | -16.7% | 0.00% | -100.0% |
| Q3 2022 | $6,262,000 | -15.1% | 480,542 | -17.4% | 0.00% | 0.0% |
| Q2 2022 | $7,376,000 | -22.7% | 582,105 | -14.5% | 0.00% | 0.0% |
| Q1 2022 | $9,538,000 | +281.5% | 680,859 | +688.8% | 0.00% | – |
| Q4 2021 | $2,500,000 | -40.2% | 86,321 | -38.2% | 0.00% | -100.0% |
| Q3 2021 | $4,181,000 | -64.4% | 139,573 | -68.5% | 0.00% | -50.0% |
| Q2 2021 | $11,753,000 | +301.9% | 443,038 | +371.1% | 0.00% | – |
| Q1 2021 | $2,924,000 | +911.8% | 94,043 | +969.0% | 0.00% | – |
| Q4 2020 | $289,000 | +381.7% | 8,797 | +409.1% | 0.00% | – |
| Q3 2020 | $60,000 | – | 1,728 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |